BACKGROUND & AIMS: In patients with chronic hepatitis B virus (HBV) infection, persistent
exposure to high concentrations of antigen can disrupt T-cell functions. It is not clear to what …

Therapy of chronic hepatitis delta with standard interferon therapy has met with limited
efficacy. This study was designed to examine the efficacy and safety of peginterferon with or …

Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma
have increased the complexity of patient management. A dynamic adaptation of the available …

Background & Aims Despite the excellent efficacy of direct‐acting antivirals ( DAA ) reported
in clinical trials, virological failures can occur, often associated with the development of …

Background The differential diagnosis of Fever of Unknown Origin (FUO) is very extensive,
and includes infectious diseases (ID), neoplasms and noninfectious inflammatory diseases (…

Background Data on the prevalence of hepatitis C virus (HCV) infection in Italy are outdated
and usually derived from studying residents in small towns. Methods To assess prevalence …

Population testing remains central to COVID-19 control and surveillance, with countries
increasingly using antigen tests rather than molecular tests. Here we describe a SARS-CoV-2 …

Background Suppression of hepatitis B virus (HBV) replication with nucelos(t)ide analogues
should be considered for patients with chronic hepatitis D virus (HDV) infection and ongoing …

Background & Aims Advances in direct‐acting antiviral treatment of HCV have reinvigorated
public health initiatives aimed at identifying affected individuals. We evaluated the possible …

Background Few data are available on the virological and clinical outcomes of advanced
liver disease patients retreated after first-line DAA failure. Aim To evaluate DAA failure …